Placebo Controlled Study of Sublingual Salvinorin A (6A)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01149824
: June 24, 2010
Last Update Posted
: May 31, 2013
California Pacific Medical Center Research Institute
Information provided by (Responsible Party):
John Mendelson, MD, California Pacific Medical Center Research Institute
In this study, our aim is to determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. This study is an ascending-dose, placebo-controlled, single-site design in 8 Salvia-experienced subjects. Subjects will receive SA doses from 0-4000 µg. Doses will be separated by at least one day. The first two doses (0 and 100µg) will be double-blinded while the last four (250, 500, 1000, 2000 and 4000µg) will be single-blind.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
21 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female, aged 21-45
Experienced with hallucinogenic amounts of SA
Good physical and mental health
Able to give adequate informed consent
Any medical or psychiatric condition which, in the investigators' opinion, would preclude safe or consistent participation
Significant acute or chronic medical disease
Female who is pregnant, lactating, or plans to become pregnant during the study period and within one month after study drug administration